Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 20/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38315 | 0.98 | KIF11 (1.00) | KIF11 | |
| Cysteamine SCHEMBL3970283 | 0.92 | KIF11 (0.81) | KIF11 | |
| SCHEMBL20101561 | 0.87 | KIF11 (1.00) | KIF11 | |
| SCHEMBL14945645 | 0.87 | KIF11 (1.00) | KIF11 | |
| SCHEMBL19371248 | 0.85 | KIF11 (0.77) | KIF11 | |
| Hydrochloric Acid SCHEMBL28040656 | 0.84 | KIF11 (0.69) | KIF11 | |
| Trifluoroacetic Acid SCHEMBL7734330 | 0.84 | KIF11 (0.73) | KIF11 | |
| SCHEMBL25400195 | 0.83 | KIF11 (0.74) | KIF11 | |
| SCHEMBL12417490 | 0.82 | KIF11 (1.00) | KIF11 | |
| SCHEMBL98804 | 0.82 | KIF11 (0.71) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102525-A1 | COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF | SILBER B MICHAEL (US) | 2026-04-16 | — | — | US | disclosed |
| US-12465660-B2 | Compositions and methods for cancer imaging and radiotherapy | VECT-HORUS (FR) | 2025-11-11 | — | — | US | disclosed |
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2025-10-02 | — | — | US | disclosed |
| US-20250255992-A1 | COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF | REILEY PHARMACEUTICALS INC (US) | 2025-08-14 | — | — | US | disclosed |
| EP-4490152-A1 | ACTIVATORS OF EFFECTOR T CELLS | Orum Therapeutics Inc. (KR) | 2025-01-15 | — | — | EP | disclosed |
| CN-119303102-A | Double-target cyclopeptide coupling medicine, medicine composition and application thereof | 博瑞生物医药（苏州）股份有限公司 | 2025-01-14 | — | — | CN | disclosed |
| US-20240358866-A1 | NSAID-DERIVED CONJUGATE COMPOUNDS FOR IMAGING | REILEY PHARMACEUTICALS INC (US) | 2024-10-31 | — | — | US | disclosed |
| WO-2024118818-A1 | NSAID-DERIVED CONJUGATE COMPOUNDS FOR IMAGING | Reiley Pharmaceuticals, Inc. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20240100204-A1 | COMPOSITIONS AND METHODS FOR CANCER IMAGING AND RADIOTHERAPY | VECT-HORUS (FR) | 2024-03-28 | — | — | US | disclosed |
| US-20230390308-A1 | URSODEOXYCHOLIC ACID DERIVATIVES FOR THE TREATMENT OF POLYCYSTIC DISEASES | UNIV DEL PAIS VASCO/EUSKAL HERRIKO UNIBERTSITATEA (ES) | 2023-12-07 | — | — | US | disclosed |
| EP-2077267-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-07-08 | — | — | EP | disclosed |
| EP-1873144-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-01-02 | — | — | EP | disclosed |
| US-20070207947-A1 | Stabilized Peptides | APLAGEN GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| EP-1673386-A2 | STABILIZED ALPHA-HELICAL PEPTIDES | AplaGen GmbH (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040202-A2 | STABILIZED ALPHA-HELICAL PEPTIDES | APLAGEN GMBH (DE) | 2005-05-06 | — | — | WO | disclosed |
| US-6448058-B1 | METHOD OF INHIBITING A PEPTIDE DEFORMYLASE, THE METHOD COMPRISING CONTACTING THE PEPTIDE DEFORMYLASE WITH ONE OR MORE COMPOUNDS OF THE INVENTION | VERSICOR, INC. | 2002-09-10 | — | — | US | disclosed |
| US-4394520-A | SKIN DISORDERS | SOCIETE ANONYME DITE: L'OREAL (FR) | 1983-07-19 | — | — | US | disclosed |
| US-4204064-A | FOR TREATMENT OF SKIN OR SCALP | L'OREAL (FR) | 1980-05-20 | — | — | US | disclosed |
| US-4085217-A | DERIVATIVES OF CYSTEINE OR CYSTEAMINE | L'OREAL (FR) | 1978-04-18 | — | — | US | disclosed |
| US-3976781-A | SULFUR CONTAINING AMINES | L'OREAL (FR) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230390308-A1 | URSODEOXYCHOLIC ACID DERIVATIVES FOR THE TREATMENT OF POLYCYSTIC DISEASES | PKD1, PKD2, SLC10A1 | KIF11 558/4885 |
| US-20070207947-A1 | Stabilized Peptides | PTMS, VIP, SPPL2A | KIF11 2555/4885 |
| US-20250255992-A1 | COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF | PTGES2, PTGES, OPRK1 | KIF11 4386/4885 |
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | CBLB, CBL, CBLC | KIF11 3110/4885 |
| US-20260102525-A1 | COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF | OPRK1, OPRD1, OPRM1 | KIF11 3993/4885 |
| US-20240358866-A1 | NSAID-DERIVED CONJUGATE COMPOUNDS FOR IMAGING | PTGES2, PTGS2, PTGES | KIF11 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.